| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Ventyx Biosciences Inc. | VTX958 | Crohn's disease | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Ventyx Biosciences Inc. | VTX3232 | Parkinson's disease | Phase 2a | Ongoing | Oral | Neurology |
| Vera Therapeutics Inc. | Atacicept - (ORIGIN 3) | IgA Nephropathy | PDUFA priority review | Ongoing | Subcutaneous | Immunology |
| Vera Therapeutics Inc. | Atacicept | Lupus nephritis (LN) | Phase 3 | Trial Planned | Subcutaneous | Immunology |
| Vera Therapeutics Inc. | MAU868 | Kidney transplant | Phase 2 | Ongoing | Intravenous | Immunosuppressant |
| Vera Therapeutics Inc. | Atacicept - (PIONEER) | Expanded IgAN populations | Phase 2 | Ongoing | Subcutaneous | Immunology |
| Vera Therapeutics Inc. | Atacicept - (JANUS) | IgA nephropathy (IgAN) | Phase 2a | Ongoing | Subcutaneous | Immunology |
| Veracyte Inc. | NRG/RTOG 0521 - (STREAM) | Prostate cancer | Phase 3 | Ongoing | Intravenous | Oncology |